Medical Policy Updates

Table Of Contents

Notification of Policy Revisions Effective July 1, 2014 (Posted April 29, 2014)

Medical Policy Revision
Laboratory and Genetic Testing for Use of 5-Fluorouracil in Patients with Cancer "Notification" Policy title changed from "Laboratory Testing to Allow Area Under the Curve (AUC) Targeted 5-Fluorouracil (5-FU) Dosing for Patients Administered 5-FU for Cancer" to "Laboratory and Genetic Testing for Use of 5-Fluorouracil in Patients with Cancer". Description section updated to change the name of OnDose® to My5-FU® and to add information regarding TheraGuide®. Additional non-coverage statement added to policy indicating; "TheraGuide® testing for genetic mutations in dipyrimidine dehydrogenase (DPYD) or thymidylate synthase (TYMS) to guide 5-FU dosing and/or treatment choice in patients with cancer is considered investigational." Added the following statement to the When Not Covered section to indicate; "There is no specific CPT coding for the TheraGuide testing. The following codes may be used: 81400 and 81401. Policy Guidelines updated. Reference added. Senior Medical Director review 4/9/2014. Notification given 4/29/2014. Policy effective 7/1/2014.